| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.
|
Eur Urol
|
2012
|
4.48
|
|
2
|
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study.
|
BMJ
|
2010
|
4.42
|
|
3
|
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study.
|
BMJ
|
2013
|
3.51
|
|
4
|
Insignificant prostate cancer and active surveillance: from definition to clinical implications.
|
Eur Urol
|
2009
|
2.97
|
|
5
|
ETS gene fusions in prostate cancer: from discovery to daily clinical practice.
|
Eur Urol
|
2009
|
2.91
|
|
6
|
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications.
|
Eur Urol
|
2009
|
2.76
|
|
7
|
Castration-resistant prostate cancer: from new pathophysiology to new treatment targets.
|
Eur Urol
|
2009
|
2.72
|
|
8
|
Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells.
|
Eur Urol
|
2007
|
2.42
|
|
9
|
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.
|
Eur Urol
|
2012
|
2.27
|
|
10
|
The mutational landscape of prostate cancer.
|
Eur Urol
|
2013
|
2.14
|
|
11
|
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.
|
BJU Int
|
2008
|
1.88
|
|
12
|
Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.
|
Eur Urol
|
2011
|
1.85
|
|
13
|
Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells.
|
Cancer Res
|
2011
|
1.82
|
|
14
|
Advances in magnetic resonance imaging: how they are changing the management of prostate cancer.
|
Eur Urol
|
2011
|
1.63
|
|
15
|
Effects of NOD-like receptors in human B lymphocytes and crosstalk between NOD1/NOD2 and Toll-like receptors.
|
J Leukoc Biol
|
2010
|
1.62
|
|
16
|
A contemporary update on pathology reporting for prostate cancer: biopsy and radical prostatectomy specimens.
|
Eur Urol
|
2012
|
1.56
|
|
17
|
Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer.
|
Prostate
|
2002
|
1.54
|
|
18
|
Epigenetics in prostate cancer: biologic and clinical relevance.
|
Eur Urol
|
2011
|
1.49
|
|
19
|
Interleukin-6 activates PI3K/Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival.
|
Int J Cancer
|
2008
|
1.48
|
|
20
|
A systematic review of the volume-outcome relationship for radical prostatectomy.
|
Eur Urol
|
2013
|
1.48
|
|
21
|
Expression and signaling activity of Wnt-5a/discoidin domain receptor-1 and Syk plays distinct but decisive roles in breast cancer patient survival.
|
Clin Cancer Res
|
2005
|
1.41
|
|
22
|
Contemporary role of prostate cancer antigen 3 in the management of prostate cancer.
|
Eur Urol
|
2011
|
1.36
|
|
23
|
Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences.
|
Eur Urol
|
2008
|
1.35
|
|
24
|
miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions.
|
Int J Cancer
|
2010
|
1.32
|
|
25
|
The learning curve for laparoscopic radical prostatectomy: an international multicenter study.
|
J Urol
|
2010
|
1.30
|
|
26
|
Tumor markers in prostate cancer I: blood-based markers.
|
Acta Oncol
|
2011
|
1.28
|
|
27
|
SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas.
|
Am J Surg Pathol
|
2011
|
1.27
|
|
28
|
Multiple cellular mechanisms related to cyclin A1 in prostate cancer invasion and metastasis.
|
J Natl Cancer Inst
|
2008
|
1.18
|
|
29
|
Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues.
|
Mol Hum Reprod
|
2002
|
1.16
|
|
30
|
FGF-8 is involved in bone metastasis of prostate cancer.
|
Int J Cancer
|
2008
|
1.13
|
|
31
|
Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth.
|
Cancer Res
|
2013
|
1.12
|
|
32
|
A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.12
|
|
33
|
Upregulation of miR-96 enhances cellular proliferation of prostate cancer cells through FOXO1.
|
PLoS One
|
2013
|
1.09
|
|
34
|
beta-Microseminoprotein binds CRISP-3 in human seminal plasma.
|
Biochem Biophys Res Commun
|
2005
|
1.07
|
|
35
|
miQ--a novel microRNA based diagnostic and prognostic tool for prostate cancer.
|
Int J Cancer
|
2012
|
1.06
|
|
36
|
A prospective study on dietary fat and incidence of prostate cancer (Malmö, Sweden).
|
Cancer Causes Control
|
2007
|
1.05
|
|
37
|
The proinflammatory CXC-chemokines GRO-alpha/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids.
|
Int J Colorectal Dis
|
2007
|
1.04
|
|
38
|
REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer.
|
Nucleic Acids Res
|
2013
|
1.02
|
|
39
|
Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells.
|
PLoS One
|
2011
|
1.02
|
|
40
|
Dietary intakes of carbohydrates in relation to prostate cancer risk: a prospective study in the Malmö Diet and Cancer cohort.
|
Am J Clin Nutr
|
2012
|
1.02
|
|
41
|
Multicomponent Moraxella catarrhalis outer membrane vesicles induce an inflammatory response and are internalized by human epithelial cells.
|
Cell Microbiol
|
2010
|
1.01
|
|
42
|
Functional magnetic resonance imaging in prostate cancer.
|
Eur Urol
|
2009
|
1.01
|
|
43
|
High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression.
|
Diagn Pathol
|
2011
|
1.00
|
|
44
|
Tumour markers in prostate cancer III: biomarkers in urine.
|
Acta Oncol
|
2011
|
0.99
|
|
45
|
Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome.
|
PLoS One
|
2011
|
0.99
|
|
46
|
A role for cyclin A1 in mediating the autocrine expression of vascular endothelial growth factor in prostate cancer.
|
Oncogene
|
2005
|
0.99
|
|
47
|
Toward next generation plasma profiling via heat-induced epitope retrieval and array-based assays.
|
Mol Cell Proteomics
|
2010
|
0.99
|
|
48
|
Elevated levels and distinct patterns of expression of A-type cyclins and their associated cyclin-dependent kinases in male germ cell tumors.
|
Int J Cancer
|
2004
|
0.98
|
|
49
|
The antibacterial chemokine MIG/CXCL9 is constitutively expressed in epithelial cells of the male urogenital tract and is present in seminal plasma.
|
J Interferon Cytokine Res
|
2008
|
0.98
|
|
50
|
Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
|
Prostate
|
2008
|
0.98
|
|
51
|
β2-syntrophin and Par-3 promote an apicobasal Rac activity gradient at cell-cell junctions by differentially regulating Tiam1 activity.
|
Nat Cell Biol
|
2012
|
0.97
|
|
52
|
Male infertility and prostate cancer risk: a nested case-control study.
|
Cancer Causes Control
|
2010
|
0.97
|
|
53
|
Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis.
|
Mod Pathol
|
2011
|
0.97
|
|
54
|
Characterization and localization of cysteine-rich secretory protein 3 (CRISP-3) in the human male reproductive tract.
|
J Androl
|
2005
|
0.97
|
|
55
|
Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue.
|
Prostate
|
2005
|
0.96
|
|
56
|
Cystatin C is downregulated in prostate cancer and modulates invasion of prostate cancer cells via MAPK/Erk and androgen receptor pathways.
|
PLoS One
|
2009
|
0.96
|
|
57
|
Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
|
Am J Pathol
|
2002
|
0.92
|
|
58
|
Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients.
|
BMC Cancer
|
2010
|
0.91
|
|
59
|
Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues.
|
Prostate
|
2003
|
0.90
|
|
60
|
Serotonin activates MAP kinase and PI3K/Akt signaling pathways in prostate cancer cell lines.
|
Urol Oncol
|
2009
|
0.89
|
|
61
|
Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
|
Int J Cancer
|
2005
|
0.87
|
|
62
|
Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.
|
BJU Int
|
2006
|
0.87
|
|
63
|
Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: a laboratory study.
|
BMC Cardiovasc Disord
|
2006
|
0.87
|
|
64
|
Human eosinophils produce the T cell-attracting chemokines MIG and IP-10 upon stimulation with IFN-gamma.
|
J Leukoc Biol
|
2004
|
0.87
|
|
65
|
Intracellular co-localization of trypsin-2 and matrix metalloprotease-9: possible proteolytic cascade of trypsin-2, MMP-9 and enterokinase in carcinoma.
|
Exp Cell Res
|
2007
|
0.87
|
|
66
|
Low expression of SHP-2 is associated with less favorable prostate cancer outcomes.
|
Tumour Biol
|
2012
|
0.84
|
|
67
|
Expression and immunolocalisation of neutral endopeptidase in prostate cancer.
|
Eur Urol
|
2003
|
0.84
|
|
68
|
Cystatin C is highly expressed in the human male reproductive system.
|
J Androl
|
2004
|
0.84
|
|
69
|
ENSAM: Europium Nanoparticles for Signal enhancement of Antibody Microarrays on nanoporous silicon.
|
J Proteome Res
|
2008
|
0.83
|
|
70
|
Trypsin-2 degrades human type II collagen and is expressed and activated in mesenchymally transformed rheumatoid arthritis synovitis tissue.
|
Am J Pathol
|
2005
|
0.83
|
|
71
|
A compartmental model for biokinetics and dosimetry of 18F-choline in prostate cancer patients.
|
J Nucl Med
|
2012
|
0.83
|
|
72
|
Expression and production of the CXC chemokine growth-related oncogene-alpha by human eosinophils.
|
J Immunol
|
2003
|
0.82
|
|
73
|
A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue.
|
Biol Chem
|
2007
|
0.82
|
|
74
|
Effects of radiation therapy on tissue and serum concentrations of tumour associated trypsin inhibitor and their prognostic significance in rectal cancer patients.
|
Radiat Oncol
|
2011
|
0.81
|
|
75
|
Immunohistochemical detection of tyrosine phosphatase SHP-1 predicts outcome after radical prostatectomy for localized prostate cancer.
|
Int J Cancer
|
2010
|
0.81
|
|
76
|
Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
|
Cancer Biother Radiopharm
|
2012
|
0.80
|
|
77
|
Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines.
|
Urol Oncol
|
2002
|
0.80
|
|
78
|
Constitutive expression of the antibacterial CXC chemokine GCP-2/CXCL6 by epithelial cells of the male reproductive tract.
|
J Reprod Immunol
|
2008
|
0.80
|
|
79
|
Midkine is part of the antibacterial activity released at the surface of differentiated bronchial epithelial cells.
|
J Innate Immun
|
2013
|
0.80
|
|
80
|
Automatic registration of multi-modal microscopy images for integrative analysis of prostate tissue sections.
|
BMC Cancer
|
2013
|
0.79
|
|
81
|
Identification of plasma protein profiles associated with risk groups of prostate cancer patients.
|
Proteomics Clin Appl
|
2014
|
0.79
|
|
82
|
Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6.
|
EJNMMI Res
|
2014
|
0.78
|
|
83
|
Lipopolysaccharide-binding protein is produced in the epididymis and associated with spermatozoa and prostasomes.
|
J Reprod Immunol
|
2005
|
0.78
|
|
84
|
High expression of midkine in the airways of patients with cystic fibrosis.
|
Am J Respir Cell Mol Biol
|
2013
|
0.78
|
|
85
|
PSA and prostate cancer screening: the challenge of the new millennium.
|
Eur Urol
|
2007
|
0.78
|
|
86
|
The pentraxin serum amyloid P component is found in the male genital tract and attached to spermatozoa.
|
Int J Androl
|
2007
|
0.78
|
|
87
|
Topical steroids do not downregulate expression of growth-related oncogene-alpha in nasal polyps.
|
Acta Otolaryngol
|
2006
|
0.77
|
|
88
|
Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.
|
World J Urol
|
2015
|
0.77
|
|
89
|
Role of histopathology and molecular markers in the active surveillance of prostate cancer.
|
Acta Oncol
|
2011
|
0.77
|
|
90
|
PCA3 as a diagnostic marker for prostate cancer: a validation study on a Swedish patient population.
|
Scand J Urol Nephrol
|
2010
|
0.76
|
|
91
|
TCF7L2 type 2 diabetes risk variant, lifestyle factors, and incidence of prostate cancer.
|
Prostate
|
2014
|
0.76
|
|
92
|
Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancer.
|
Cancer Med
|
2012
|
0.76
|
|
93
|
Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder.
|
World J Urol
|
2011
|
0.76
|
|
94
|
"A robot saved my life": is it a myth?
|
Eur Urol
|
2012
|
0.75
|
|
95
|
Genetic markers and the risk of developing prostate cancer.
|
Eur Urol
|
2011
|
0.75
|
|
96
|
Circulating tumour cells as surrogate biomarkers in castration-resistant prostate cancer trials.
|
Eur Urol
|
2011
|
0.75
|
|
97
|
Copy number variants in the kallikrein gene cluster.
|
PLoS One
|
2013
|
0.75
|
|
98
|
Correction: Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.
|
PLoS One
|
2016
|
0.75
|
|
99
|
Interobserver variability in the pathological assessment of radical prostatectomy specimens: findings of the Laparoscopic Prostatectomy Robot Open (LAPPRO) study.
|
Scand J Urol
|
2013
|
0.75
|
|
100
|
Plasma alkylresorcinol metabolites as biomarkers for whole-grain intake and their association with prostate cancer: a Swedish nested case-control study.
|
Cancer Epidemiol Biomarkers Prev
|
2013
|
0.75
|
|
101
|
PROQUR: a tool for quality control, epidemiological surveillance, patient follow-up and clinical research activities related to prostate cancer.
|
Acta Oncol
|
2005
|
0.75
|